Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Yves Fradet(Université Laval), Joaquim Bellmunt(Municipal Institute for Medical Research), David J. Vaughn(Abramson Cancer Center), J L Lee(Asan Medical Center), Lawrence Fong(University of California, San Francisco), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), M.Á. Climent(Fundación Instituto Valenciano de Oncología), Daniel P. Petrylak(Yale University), Toni K. Choueiri(Dana-Farber Cancer Institute), Andrea Necchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Winald R. Gerritsen(Radboud University Medical Center), Howard Gurney(Westmead Hospital), David I. Quinn(University of Southern California), Stéphane Culine(Hôpital Saint-Louis), Cora N. Sternberg(Cornell University), K. Nam(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tara L. Frenkl(Merck & Co., Inc., Rahway, NJ, USA (United States)), Rodolfo F. Perini(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ronald de Wit(Erasmus MC Cancer Institute), Dean F. Bajorin(Memorial Sloan Kettering Cancer Center)
Cited by 484Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis